Home/All Molecules/Rifaximin

Rifaximin Range

Comprehensive Rifaximin portfolio for Franchise & Manufacturing.

Category
rifaximin
Total Formulations
7
Available Forms
Syrup, Tablets

Expand Your Business with Our Multiple Divisions


Browse Rifaximin portfolio by Dosage Form


The Cafoli Advantage for PCD Franchise & Manufacturing

WHO-GMP Quality

Every Rifaximin batch undergoes rigorous in-house and third-party testing, strictly adhering to WHO-GMP standards for efficacy and safety.

Quality Policy

Monopoly & Branding

Secure exclusive PCD franchise rights for your territory and benefit from our range of premium, marketing-driven product packaging.

Market Strategy

Sales Support

Enhance your sales with Cafoli’s complete kit of marketing materials, including visual aids, MR bags, catch covers, and product cards.

Marketing Tools

Rifaximin PCD Pharma Franchise

Rifaximin PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Rifaximin PCD pharma franchise company offering a portfolio of 7 Rifaximin formulations across tablets and syrup. Every batch is manufactured at DCGI-approved facilities and supplied to franchise partners with district-level monopoly rights, ready-to-use promotional inputs and dependable stock availability.

What is Rifaximin?

Rifaximin is a non-absorbed, gut-selective antibiotic derived from rifamycin. It inhibits bacterial DNA-dependent RNA polymerase but stays almost entirely within the gastrointestinal lumen, giving a broad antibacterial effect in the gut with minimal systemic exposure. The compound record can be reviewed on PubChem.

Therapeutic Applications

Travellers diarrhoea, hepatic encephalopathy (for reduction of recurrence), irritable bowel syndrome with diarrhoea, and small intestinal bacterial overgrowth. It is also used in some hepatology protocols alongside lactulose.

Prescribed by: Gastroenterologists and hepatologists are the leading prescribers of Rifaximin, followed by general physicians managing infective diarrhoea and IBS.

Why Rifaximin is a High-Potential Molecule for Distributors

Rifaximin has an unusual commercial profile for an antibiotic: because it is barely absorbed, it is prescribed in long, repeating courses for hepatic encephalopathy and IBS-D rather than as a short one-week antibiotic course. That turns it into a chronic, refill-driven line inside a gastro portfolio. Liver disease and IBS are both under-served and rising in India, and prescriptions concentrate with gastroenterologists and hepatologists, so a distributor who builds relationships with a handful of specialists can generate disproportionate volume from a small prescriber base.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers its Rifaximin franchise partners genuine monopoly rights for their allotted district or territory, products manufactured in WHO-GMP certified, DCGI-approved units, and complete promotional support — visual aids, MR bags, sample packs, product cards and doctor gifting. With 1000+ channel partners across India, on-time dispatch and transparent net rates, we make it straightforward to build a profitable Rifaximin business in your region.

References

  1. PubChem – Rifaximin compound record, US National Library of Medicine
  2. PubMed – clinical literature on Rifaximin, NCBI

Aceclofenac in Modern Clinical Practice

Our formulations of Rifaximin find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to:


FAQ about Rifaximin in PCD Franchise

Start Your Rifaximin Franchise with Cafoli Lifecare

Ready to take monopoly rights for Rifaximin in your district? Talk to our franchise team for net rates, packing details and the current availability list. Call 9518447302 or email info@cafoli.in.

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions (FAQs)

Cafoli Lifecare offers 7 Rifaximin formulations in tablets and syrup. The current list with packing and net rates is shared with registered franchise enquiries.

Yes. Monopoly rights for the Rifaximin range are allotted district-wise on a first-come basis and are confirmed in your franchise agreement, so no other Cafoli partner sells the same brands in your territory.

Gastroenterologists and hepatologists are the leading prescribers of Rifaximin, followed by general physicians managing infective diarrhoea and IBS.

Rifaximin acts almost entirely within the gut lumen with minimal systemic absorption, so hepatologists and gastroenterologists can use it in extended, repeating courses for hepatic encephalopathy recurrence and IBS with diarrhoea. Commercially this means refill-driven, chronic demand rather than the short single-course pattern typical of systemic antibiotics.

You need a valid Drug License and a GST registration in your name. Once these are shared along with your territory preference, the Rifaximin franchise agreement and monopoly allotment can be processed.